Abstract
The diagnostic work-up of CUP patients should be guided on one hand by the usually limited life expectancy of this patient group and on the other hand by the fact that CUP comprises a minority of patients with a clearly better prognosis if treated correctly. Hence, the diagnostic process should be fast and efficient, avoid studies whose results are not expected to alter clinical management, and focus on identifying patient subsets benefiting from specific approaches. We here discuss the implementation of novel methods into routine diagnostics, paying special attention to the fact that there are marked differences between different health care systems, e.g., regarding gene expression-based site-of-origin assignment, which can be widely offered to CUP patients in the USA but not in most other countries including Germany. Finally, we present our own practical approach towards the diagnostic work-up of CUP patients.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med. 1986;104(4):547–53. PubMed.
Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol. 1992;10(6):912–22. PubMed.
Hainsworth JD, Wright EP, Johnson DH, Davis BW, Greco FA. Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining. J Clin Oncol. 1991;9(11):1931–8. PubMed.
Seve P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer. 2007;109(2):292–9. PubMed.
Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, Edmonston TB, et al. A second-generation microRNA-based assay for diagnosing tumor tissue origin. Oncologist. 2012;17(6):801–12. PubMed Central PMCID: 3380879.
Erlander MG, Ma XJ, Kesty NC, Bao L, Salunga R, Schnabel CA. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn. 2011;13(5):493–503. PubMed Central PMCID: 3157614.
Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah cannon research institute. J Clin Oncol. 2013;31(2):217–23. PubMed.
Hainsworth JD, Spigel DR, Thompson DS, Murphy PB, Lane CM, Waterhouse DM, et al. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist. 2009;14(12):1189–97. PubMed.
Martineau G, Laplanche A, Van de Wouw AW, Gedske Daugaard G, Balana C, Penel N, et al. GEFCAPI 04: a phase III trial comparing a treatment oriented by a molecular analysis with CancerTYPE ID test to cisplatin-gemcitabine in patients with carcinoma of an unknown primary (CUP). J Clin Oncol. 2014;32, TPS11134.
Tothill RW, Li J, Mileshkin L, Doig K, Siganakis T, Cowin P, et al. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J Pathol. 2013;4. PubMed.
Varadhachary GR, Karanth S, Qiao W, Carlson HR, Raber MN, Hainsworth JD, et al. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol. 2013;28. PubMed.
Strojan P, Ferlito A, Medina JE, Woolgar JA, Rinaldo A, Robbins KT, et al. Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck. 2013;35(1):123–32. PubMed.
Cerezo L, Raboso E, Ballesteros AI. Unknown primary cancer of the head and neck: a multidisciplinary approach. Clin Transl Oncol. 2011;13(2):88–97. PubMed.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Krämer, A., Löffler, H. (2016). Diagnostic Work-up of CUP: An Approach to Current Recommendations and Underlying Evidence. In: Krämer, A., Löffler, H. (eds) Cancer of Unknown Primary. Springer, Cham. https://doi.org/10.1007/978-3-319-22581-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-22581-4_5
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-22580-7
Online ISBN: 978-3-319-22581-4
eBook Packages: MedicineMedicine (R0)